#South Korea #Seoul #Botulinum Toxin #SOLTOX #CELSET

CELSET Introduces SOLTOX to Global Markets

On October 28, 2026, CELSET INC., a renowned South Korean biotech company, made a significant mark on the global aesthetic medicine landscape by launching SOLTOX, its proprietary brand of botulinum toxin type A products. This launch is part of CELSET’s broader strategy to expand its reach in the international aesthetic medicine market.

About SOLTOX

SOLTOX is engineered to enhance the aesthetic experience and is available in two configurations: 100 and 200 units of botulinum toxin. It boasts advanced technical features, including a 900 kDa molecular weight complex, a lyophilized pharmaceutical form, and cutting-edge purification processes. Each of these attributes reflects CELSET’s commitment to excellence in manufacturing, emphasizing strict process controls, product characteristics, and pharmaceutical quality.

The 900 kDa designation refers to the molecular weight of the botulinum toxin’s protein complex, which includes accompanying proteins. While this attribute contributes to specific properties of the product, it does not imply that SOLTOX offers extended efficacy or longer-lasting results compared to competitors. The formulation is presented as a lyophilized powder, requiring reconstitution before administration by qualified medical personnel, aligning with the product documentation and local regulations.

Advanced Purification Technology

A key aspect of the SOLTOX manufacturing process is the advanced botulinum toxin purification technology employed, aimed at isolating the desired substance from unwanted components. Production occurs under controlled conditions, adhering to quality control procedures at various stages: preparation, packaging, lyophilization, and assessment of production batches. CELSET prioritizes these production characteristics, ensuring that they form the technological backbone of SOLTOX while communicating the unique formulation specifications to the medical community.

Brand Identity and Market Positioning

The introduction of SOLTOX represents a strategic advancement in CELSET’s international endeavors within the aesthetic medicine sector. The brand’s positioning reflects an increasing recognition of the South Korean biotech industry and its role in aesthetic medicine innovation. Additionally, it highlights the importance of established partnerships with the medical environment and adherence to respective regulations across markets.

CELSET asserts that strengthening its international presence hinges on developing relationships with the medical community and advancing its operational scope in various domestic markets. This launch adds to CELSET’s extensive range of aesthetic medicine offerings, reaffirming its commitment to disseminating reliable, scientifically-grounded information regarding its products. The company stresses the importance of maintaining a coherent brand image and providing clear, comprehensible information about its products to medical professionals in varied markets.

Commitment to Aesthetic Medicine

CELSET INC. is based in Seoul, South Korea, and specializes in the aesthetic medical sector. The launch of SOLTOX underscores CELSET’s dedication to creating prominent brands, adhering to production standards for aesthetic products, and engaging in professional communication within the global aesthetic market. With SOLTOX, CELSET aims to reshape the aesthetic landscape, ensuring that its products are not only effective but also recognized and trusted worldwide.

For more information about SOLTOX and its offerings, visit CELSET Aesthetics.